Tg(tetO-EGFR*T790M*L858R)51Paow
Transgene Detail

Summary

• Symbol: Tg(tetO-EGFR*T790M*L858R)51Paow
• Name: transgene insertion 51, William Pao
• MGI ID: MGI:5705251
• Synonyms: EGFR^L858R+T790M, line 51
• Transgene: Tg(tetO-EGFR*T790M*L858R)51Paow Location: unknown
• Alliance: Tg(tetO-EGFR*T790M*L858R)51Paow page

Transgene origin

• Strain of Origin: FVB/N

Transgene description

• Transgene Type: Transgenic (Humanized sequence, Inducible, Inserted expressed sequence)
• Inducer: doxycycline/tetracycline
• Mutation: Insertion
• Tg(tetO-EGFR*T790M*L858R)51Paow expresses 1 gene
  Transgene expresses:
  

  Organism

  Expressed Gene

  Homolog in Mouse

  Note

  human

  EGFR (1956)

  Egfr	(MGI:95294)

• Mutation details: A mutant human epidermal factor receptor cDNA with a C-to-T nucleotide substitution in exon 20 that replaces threonine with methionine at amino acid position 790 (T790M) and a T-to-G nucleotide substitution in exon 21 that replaces leucine with arginine at amino acid position 858 (L858R) was cloned between a tetracycline-responsive element and an intron and polyadenylation signal from the mouse protamine 1 gene. Mice with this transgene that express the tetracycline transactivator (tTA) or reverse transactivator (rtTA) under control of a tissue-specific promotor can be induced to express the mutant gene in tissues or cell types of interest by administration/withdrawal of doxycycline. Three founders were established: 12, 29, and 51, and line 51 is entered as a representative line. (J:128700)

Disease models

Expression

In Structures Affected by this Mutation:

1 anatomical structure(s)

Tumor Data

List all tumor models in MMHCdb carrying Tg(tetO-EGFR*T790M*L858R)51Paow

Find Mice (IMSR)

• Mouse strains and cell lines available from the International Mouse Strain Resource (IMSR)
• Carrying this Mutation: Mouse Strains: 0 strains available Cell Lines: 0 lines available

References

• Original: J:128700 Regales L, et al., Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One. 2007;2(8):e810
• All: 4 reference(s)